# Cerebrolysin

Source: https://aminodesk.com/library/cerebrolysin
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

Cerebrolysin is a mixture of peptides made from pig brain tissue. More than 50 countries have approved it for stroke and dementia. The US has not, and the independent reviews that pooled its trials did not find a convincing benefit.

- **Legal lane:** approved in more than 50 countries. Not FDA-approved for any use.
- **Evidence grade:** B. Many randomized trials; independent reviews find the benefit unproven.
- **Form:** injection into a vein or muscle
- **What it is:** a mixture, not a single peptide

## What it is

A preparation derived from pig brain, first described in Austria in 1949 and made by an Austrian company. It is used in parts of Europe, Asia and Latin America for stroke, traumatic brain injury and dementia. Nootropic users import it for memory and brain recovery.

## What the evidence shows

- **Stroke:** the 2023 Cochrane review pooled 7 randomized trials with 1,773 participants. It found no benefit on death from any cause, and a higher rate of serious adverse events that were not fatal.
- **Vascular dementia:** an earlier Cochrane review could not reach a definite conclusion, and its 2019 update found no new trials.
- **Pattern:** the positive results come mainly from trials sponsored by the manufacturer, without independent confirmation.

This is one of the most thoroughly reviewed products in this library. Its wide use abroad does not reflect strong evidence that the FDA overlooked.

## Legal status

- Not FDA-approved for any use.
- A prescription medicine in the countries that have approved it.
- Buying it abroad or online for personal use is importing an unapproved drug.

## Reported dosing

**We do not publish a protocol for this compound.**

Countries that approve it have their own labels, which we have not checked directly. It is given by infusion or injection under medical supervision.

## Safety

- The Cochrane stroke review found more non-fatal serious adverse events with Cerebrolysin than without it.
- It is an animal tissue product given by injection or infusion.
- Stroke, head injury and dementia need medical care. An imported product is not a substitute.

## Common questions

### Is Cerebrolysin FDA-approved?

No. It is approved in more than 50 other countries.

### Does Cerebrolysin work for stroke?

The 2023 Cochrane review of 7 trials and 1,773 patients found no benefit on death and more serious adverse events.

### Is Cerebrolysin a peptide?

It is a mixture of peptides and amino acids made from pig brain, not a single defined peptide.

## Sources

- [Superpower: Cerebrolysin status and the 2023 Cochrane findings](https://superpower.com/guides/peptides/cerebrolysin)
- [Cochrane: Cerebrolysin for vascular dementia](https://www.cochrane.org/evidence/CD008900_cerebrolysin-vascular-dementia)
- [Cochrane review, 2019 update: Cerebrolysin for vascular dementia (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6844361)
- [Empire Medical Training: how to read its use abroad](https://www.empiremedicaltraining.com/antiaging-regenerative-workshops/resources/peptide-therapy/cerebrolysin/)
- [Peptide Journal: history and administration](https://peptidejournal.org/peptides/cerebrolysin-neuropeptide-research-overview)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
